Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.
Y Fong, J Fortner, R L Sun...
https://pubmed.ncbi.nlm.nih.gov/10493478/Actively Recruiting
Led by National Cancer Institute (NCI) · Updated on 2026-10-23
332
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are studying an experimental immunotherapy using tumor-infiltrating lymphocytes TIL in adults aged 18 to 72 with metastatic cancers including digestive tract, urothelial, breast, ovarianendometrial, and endocrine tumors that have not responded to standard chemotherapy. The study aims to evaluate whether specially selected TIL can shrink tumors and to assess the safety of this treatment. This phase II trial is sponsored by the National Cancer Institute and explores combining TIL therapy with chemotherapy and pembrolizumab. Participants first undergo evaluation including scans, lab tests, and tumor removal surgery to grow the TIL cells. They may also have leukapheresis to collect additional white blood cells. After TIL cells are prepared, patients receive a lymphodepleting chemotherapy regimen followed by infusion of TIL cells and high-dose aldesleukin in the hospital, along with pembrolizumab either before cell infusion or upon disease progression depending on the group. Hospital stay for treatment lasts about 4 weeks. During the study, participants return for follow-up visits every 1 to 3 months in the first year, then every 6 months to a year while tumors shrink. Follow-up includes physical exams, side effect reviews, lab tests, and scans, taking up to two days per visit. Researchers measure tumor response rates at multiple time points after infusion and monitor safety and adverse events. Total study participation may extend for multiple years depending on response and follow-up needs.
CONDITIONS
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
N
NCI/Surgery Branch Recruitment Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Cancer Institute (NCI)
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | CD8+ Enriched TIL (closed, enrollment completed) | Unselected TIL (closed, enrollment completed) | Unselected TIL + Pembrolizumab before cell infusion | Unselected TIL + Pembrolizumab at progression |
|---|---|---|---|---|
| What it is | Autologous tumor-infiltrating lymphocyte (TIL) therapy using CD8+ T cells grown from a participant's own tumor, following lymphodepleting chemotherapy. | Autologous TIL therapy with unselected lymphocytes expanded from the participant's tumor, using similar lymphodepleting chemotherapy. | Autologous unselected TIL therapy after lymphodepleting chemotherapy, plus pembrolizumab (an immunotherapy drug) given before TIL cell infusion. | Autologous unselected TIL therapy after lymphodepleting chemotherapy, with pembrolizumab given only if disease progresses after cell infusion. |
| Primary use or goal | To evaluate the feasibility and anti-tumor activity of CD8+ enriched autologous TIL therapy in adults with refractory metastatic solid tumors. | To assess the effect of unselected TIL therapy in treating refractory metastatic cancers when standard therapies have failed. | To study whether adding pembrolizumab before TIL infusion can enhance the therapeutic response to autologous TIL therapy. | To determine the effectiveness of TIL therapy when pembrolizumab is reserved for use after progression. |
| How it is given or performed | Participants undergo tumor resection to harvest cells, lymphodepleting chemotherapy (cyclophosphamide plus fludarabine), then receive intravenous infusion of CD8+ enriched TILs, followed by high-dose aldesleukin. | Emerges from tumor resection and cell growth, followed by the same lymphodepleting chemotherapy, intravenous infusion of unselected TILs, and high-dose aldesleukin. | Participants receive pembrolizumab (2 mg/kg IV) before TIL infusion, in addition to tumor harvest, preparative chemotherapy (cyclophosphamide and fludarabine), TIL infusion, and high-dose aldesleukin. | Follows TIL harvest, preparative chemotherapy, TIL infusion, and post-infusion high-dose aldesleukin; pembrolizumab is provided only if the participant's disease progresses after TIL therapy. |
| Maturity of evidence | Evidence from early-phase trials supports feasibility; results for long-term anti-tumor effect are limited and patient benefit is still under investigation. | Early clinical reports show TIL therapy is feasible in some solid tumors; significant clinical benefit for metastatic GI, breast, and endocrine tumors remains investigational. | Combination approaches are supported mainly by early-phase studies showing proof-of-principle for immune response; overall efficacy and broader patient benefit are uncertain. | Evidence for delayed pembrolizumab post-TIL is limited; combination sequencing is under exploration, with results awaited. |
| Important limitations | Requires surgery to obtain tumor tissue, intensive cell manufacturing, and high-dose immune therapy, which may not be suitable for all patients. Long-term outcomes are not yet established. | Cell therapy requires highly specialized expertise; adverse effects can arise from chemotherapy and cytokine support. Durable benefit may not occur for all patients. | Potential for overlapping immune-related adverse events exists; data about added efficacy versus toxicity is limited, and the protocol is complex. | Uncertainty remains around sequencing benefit; adverse effects of immunotherapy still possible, and no proven strategy yet exists for this order of treatment. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility through history, physical exams, scans, lab tests, and other evaluations.
1 to 2 visits
Duration - 1 to 2 weeks
Participants undergo surgery to remove tumor tissue needed to grow the tumor-infiltrating lymphocytes for treatment.
1 surgical visit
Duration - 1 day
Some participants may have white blood cells collected through leukapheresis to support TIL production.
1 procedure visit
Duration - About 4 weeks
Participants receive lymphodepleting chemotherapy followed by infusion of TIL cells, high-dose aldesleukin, and pembrolizumab according to their study group during a hospital stay.
Continuous hospital stay
Duration - Up to 2 years or more
Participants return for regular follow-up visits including physical exams, side effect reviews, lab tests, and imaging to monitor tumor response and safety.
Visits every 1-3 months in first year, then every 6-12 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Have more questions? Get in touch with our team for quick support
Y Fong, J Fortner, R L Sun...
https://pubmed.ncbi.nlm.nih.gov/10493478/Eric Tran, Simon Turcotte, Alena Gros...
https://pubmed.ncbi.nlm.nih.gov/24812403/Noam Levin, Sanghyun P Kim, Charles A Marquardt...
https://pubmed.ncbi.nlm.nih.gov/38816232/Frank J Lowery, Stephanie L Goff, Billel Gasmi...
https://pubmed.ncbi.nlm.nih.gov/40169866/James S Tomlinson, William R Jarnagin, Ronald P DeMatteo...
https://pubmed.ncbi.nlm.nih.gov/17925551/T Chiba, H Ohtani, T Mizoi...
https://pubmed.ncbi.nlm.nih.gov/15494715/Nikolaos Zacharakis, Lutfi M Huq, Samantha J Seitter...
https://pubmed.ncbi.nlm.nih.gov/35104158/Parisa Malekzadeh, Anna Pasetto, Paul F Robbins...
https://pubmed.ncbi.nlm.nih.gov/30714987/National Cancer Institute (NCI)
Lead Sponsor